NYSE American - Delayed Quote • USD
VolitionRx Limited (VNRX)
At close: April 18 at 3:59 PM EDT
After hours: April 18 at 5:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | -0.11 | -0.11 | -0.41 | -0.32 |
| Low Estimate | -0.12 | -0.12 | -0.48 | -0.41 |
| High Estimate | -0.1 | -0.1 | -0.35 | -0.25 |
| Year Ago EPS | -0.15 | -0.14 | -0.5 | -0.41 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | 390k | 630k | 3.63M | 15.59M |
| Low Estimate | 270k | 470k | 3M | 8.3M |
| High Estimate | 500k | 900k | 4.7M | 21.8M |
| Year Ago Sales | 420k | 216k | 775k | 3.63M |
| Sales Growth (year/est) | -7.10% | 191.70% | 368.40% | 329.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.14 | -0.15 | -0.13 | -0.11 |
| EPS Actual | -0.15 | -0.14 | -0.11 | -0.11 |
| Difference | -0.01 | 0.01 | 0.02 | 0 |
| Surprise % | -7.10% | 6.70% | 15.40% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.11 | -0.11 | -0.41 | -0.32 |
| 7 Days Ago | -0.11 | -0.11 | -0.41 | -0.32 |
| 30 Days Ago | -0.11 | -0.11 | -0.39 | -0.32 |
| 60 Days Ago | -0.11 | -0.11 | -0.39 | -0.32 |
| 90 Days Ago | -0.11 | -0.11 | -0.39 | -0.32 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VNRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 26.70% | -- | -- | 0.80% |
| Next Qtr. | 21.40% | -- | -- | 9.60% |
| Current Year | 18.00% | -- | -- | 4.50% |
| Next Year | 22.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/27/2024 |
| Maintains | EF Hutton: Buy to Buy | 3/27/2024 |
| Reiterates | EF Hutton: Buy to Buy | 1/2/2024 |
| Reiterates | EF Hutton: Buy to Buy | 11/21/2023 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 11/16/2023 |
| Initiated | EF Hutton: Buy | 10/30/2023 |
Related Tickers
P8A.SI Cordlife Group Limited
0.1350
-6.90%
ABDX.L Abingdon Health Plc
10.50
0.00%
VCYT Veracyte, Inc.
19.20
+1.80%
LAB Standard BioTools Inc.
2.5400
-2.68%
FONR FONAR Corporation
16.83
+1.85%
CSTL Castle Biosciences, Inc.
19.20
+1.91%
DMTK DermTech, Inc.
0.5910
-0.17%
ACRS Aclaris Therapeutics, Inc.
1.2300
0.00%
PSNL Personalis, Inc.
1.2100
+0.83%
PRPH ProPhase Labs, Inc.
5.44
-13.24%